CN1470524A - Polypeptide-human transcriptional elongation factor IIS51 and polynucleotide encoding this polypeptide - Google Patents
Polypeptide-human transcriptional elongation factor IIS51 and polynucleotide encoding this polypeptide Download PDFInfo
- Publication number
- CN1470524A CN1470524A CNA021362335A CN02136233A CN1470524A CN 1470524 A CN1470524 A CN 1470524A CN A021362335 A CNA021362335 A CN A021362335A CN 02136233 A CN02136233 A CN 02136233A CN 1470524 A CN1470524 A CN 1470524A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- polynucleotide
- elongation factor
- transcriptional elongation
- human transcriptional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000002508 Peptide Elongation Factors Human genes 0.000 title claims abstract description 114
- 108010068204 Peptide Elongation Factors Proteins 0.000 title claims abstract description 114
- 230000002103 transcriptional effect Effects 0.000 title claims abstract description 114
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 107
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 100
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 100
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 90
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 90
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 90
- 241000282414 Homo sapiens Species 0.000 claims abstract description 104
- 238000000034 method Methods 0.000 claims abstract description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 239000000556 agonist Substances 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- 208000026278 immune system disease Diseases 0.000 claims abstract description 4
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims abstract description 3
- 206010061218 Inflammation Diseases 0.000 claims abstract description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 3
- 230000004054 inflammatory process Effects 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 230000014509 gene expression Effects 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 238000009396 hybridization Methods 0.000 claims description 14
- 239000005557 antagonist Substances 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 238000002493 microarray Methods 0.000 claims description 3
- 238000013459 approach Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims 1
- 208000022602 disease susceptibility Diseases 0.000 claims 1
- 238000004088 simulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 238000012270 DNA recombination Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 37
- 108020004414 DNA Proteins 0.000 description 33
- 239000002299 complementary DNA Substances 0.000 description 29
- 238000005516 engineering process Methods 0.000 description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 239000000047 product Substances 0.000 description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108010069411 transcription factor S-II Proteins 0.000 description 11
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 10
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 102100026428 Transcription elongation factor A protein 2 Human genes 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000008521 reorganization Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 108091033380 Coding strand Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 108020005091 Replication Origin Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 102220369446 c.1274G>A Human genes 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 108060003552 hemocyanin Proteins 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 210000004754 hybrid cell Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100033842 General transcription factor IIF subunit 2 Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000014107 chromosome localization Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 108010014678 transcription factor TFIIF Proteins 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- UZGKAASZIMOAMU-UHFFFAOYSA-N 124177-85-1 Chemical compound NP(=O)=O UZGKAASZIMOAMU-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- 101150117081 51 gene Proteins 0.000 description 1
- 108020005075 5S Ribosomal RNA Proteins 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- MQLZLIYPFDIDMZ-HAFWLYHUSA-N Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O MQLZLIYPFDIDMZ-HAFWLYHUSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- DXJZITDUDUPINW-WHFBIAKZSA-N Gln-Asn Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O DXJZITDUDUPINW-WHFBIAKZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- XBZOQGHZGQLEQO-IUCAKERBSA-N Lys-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN XBZOQGHZGQLEQO-IUCAKERBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
- HYLXOQURIOCKIH-VQVTYTSYSA-N Thr-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N HYLXOQURIOCKIH-VQVTYTSYSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 102220023257 rs387907546 Human genes 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention discloses a polypeptide-human transcriptional elongation factor IIS51, polynucleotide for coding said polypeptide and method for producing said polypeptide by means of DNA recombination technique. Said invention also discloses the method for using said polypeptide to cure several diseases, such as malignant tumor, hemopathy, HIV infection, immunological disease and various inflammations. Said invention also discloses the agonist for resisting said polypeptide and its therapeutic action, and also discloses the application of polynucleotide coding said novel human transcriptional elongation factor IIS51.
Description
Technical field
The invention belongs to biological technical field, specifically, the invention describes a kind of polypeptide-human transcriptional elongation factor IIS 51, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the preparation method and the application of these polynucleotide and polypeptide.
Background technology
Under the catalysis of RNA polymerase, with DNA the whole process of the synthetic RNA of template, comprise steps such as initial, extension, termination, be called and transcribe.Transcribing is the first step of genetic expression, also is a step of most critical, also is the key step of gene regulating.In double-stranded DNA, be not called sense strand or coding strand, and be called antisense strand or template strand as the chain of transcribing template as the chain of transcribing template.
RNA polymerase is different with archaeal dna polymerase, and it is synthetic and do not need primer that it can an initial new chain.Eukaryote has three kinds of RNA polymerase, transcribes rRNA gene, protein gene and 5S rRNA, tRNA gene respectively.Wherein, rna plymerase ii is present in the caryoplasm, and its function is synthetic mRNA and snRNA.No matter be eukaryote or prokaryotic organism, different types of gene needs different transcription factors to assist RNA polymerase to carry out work.(molecular genetics P186-189 grandson is that grace etc. is write press of Nanjing University)
Although first RNA polymerase is separated from mammalian cell in the world, up to the present, people are nothing like the E.coliRNA polysaccharase clear like that to the understanding of eukaryotic cell RNA polymerase.
Existing discovering, the function of RNA polymerase is subjected to the regulation and control of a lot of transcription factors, and transcription factor affects the activity of RNA polymerase between extended peroid.(FASEB?J?1995?Nov；9(14)：1419-28)
Utilize a kind of new system, we can prolong from rna plymerase ii and isolate each component the mixture.(E.Bengal，A.Goldring，and?Y.Aloni，J.Biol.Chem.264：18926-18932，1989)
In the extension process of rna plymerase ii, we have found that the transcription factor that plays an important role, comprise TFIIS, TFIIF, TFIIX etc.The active function of these transcription factors depends on that whether they are in conjunction with getting on to work when rna plymerase ii runs into weak binding site.TFIIS has been found anti-weak keying action, and TFIIF and TFIIX stimulate the speed of extending.(Mol?Cell?Biol?1991?May；11(3)：1195-206)
According to research, Eukaryotic transcribing can be controlled the expression that proto-oncogene, virus comprise people's HIVvirus blood serum immunity (HIV-1).The termination site that people's transcriptional elongation factor TFIIS makes rna plymerase ii to cross in the transcription to be run into, two different functional domains of people's transcriptional elongation factor TFIIS can make it be incorporated into rna plymerase ii and polynucleotide chain.(Nature?1993?Sep16；365(6443)：277-9)
TFIIS is a kind of transcriptional elongation factor, and it begins near zone 3 ' terminal division by inducible transcription and reaches and make rna plymerase ii cross the effect that termination site continues to transcribe.But the detailed process of this mechanism is also unclear as yet.(Biochemistry?1995?Nov?21；34(46)：15375-80)
TFIIS in the different tissues of human body the specifically expressing special according to research, for example, TFIIS-K1 expression amount in tissues such as heart, lung, skeletal muscle and kidney is very high.General TFIIS is wide expression in human body then.(Genes?Cells?1998?May；3(5)：289-96)
According to amino acid homology result relatively, polypeptide of the present invention is accredited as human transcriptional elongation factor IIS 51 (HTEFIIS51) by deduction.
Summary of the invention
An object of the present invention is to provide isolating new polypeptide-human transcriptional elongation factor IIS 51 with and fragment, analogue and derivative.
Another object of the present invention provides the polynucleotide of this polypeptide of coding.
Another object of the present invention provides the recombinant vectors of the polynucleotide that contain the human transcriptional elongation factor IIS 51 of encoding.
Another object of the present invention provides the genetically engineered host cell of the polynucleotide that contain the human transcriptional elongation factor IIS 51 of encoding.
Another object of the present invention provides the method for producing human transcriptional elongation factor IIS 51.
Another object of the present invention provides the antibody at polypeptide-human transcriptional elongation factor IIS 51 of the present invention.
Another object of the present invention has provided at the simulated compound of polypeptide-human transcriptional elongation factor IIS 51 of the present invention, antagonist, agonist, inhibitor.
Another object of the present invention provides the method for the diagnoses and treatment disease relevant unusually with human transcriptional elongation factor IIS 51.
In a first aspect of the present invention, novel isolated human transcriptional elongation factor IIS 51 is provided, this polypeptide is the people source, and it comprises: have＜polypeptide of 210〉2 aminoacid sequences or its conservative property variation polypeptide or its active fragments or its reactive derivative, analogue.Preferably, this polypeptide is to have＜polypeptide of 210〉2 aminoacid sequences.
In a second aspect of the present invention, the polynucleotide of isolating these polypeptide of coding are provided, these polynucleotide comprise a nucleotide sequence, and this nucleotide sequence is shown at least 99% homogeny with a kind of nucleotides sequence that is selected from down group: (a) polynucleotide of the above-mentioned human transcriptional elongation factor IIS 51 of coding; (b) with polynucleotide (a) complementary polynucleotide.Preferably, this polynucleotide encoding have＜210〉2 shown in the polypeptide of aminoacid sequence.More preferably, the sequence of these polynucleotide is be selected from down group a kind of: (a) have＜210〉1 in the sequence of 124-1515 position; (b) have＜210〉1 in the sequence of 1-1900 position.
In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.
Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.
As used herein, " isolating " are meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.
As used herein, " isolating human transcriptional elongation factor IIS 51 " is meant that human transcriptional elongation factor IIS 51 is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying human transcriptional elongation factor IIS 51 of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.The purity of human transcriptional elongation factor IIS 51 polypeptide can be used amino acid sequence analysis.
The invention provides a kind of polypeptide-human transcriptional elongation factor IIS 51, it is basically by＜210〉aminoacid sequence shown in 2 forms.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.
The present invention also comprises fragment, derivative and the analogue of human transcriptional elongation factor IIS 51.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep identical biological function of human transcriptional elongation factor IIS 51 of the present invention or active polypeptide basically.The fragment of polypeptide of the present invention, derivative or analogue can be: (I) a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, derivative and analogue are considered within those skilled in the art's ken.
The invention provides isolating nucleic acid (polynucleotide), substantially by coding have＜polynucleotide of the polypeptide of 210〉2 aminoacid sequences form.Polynucleotide sequence of the present invention comprises＜210〉1 nucleotide sequence.Polynucleotide of the present invention are to find from the cDNA library of people's fetal brain tissue.The polynucleotide sequence total length that it comprises is 1900 bases, and its open reading frame (124---1515) 463 amino acid of having encoded.Find relatively that according to amino acid sequence homologous this polypeptide and human transcription factor TFIIS have 99% homology, deducibility goes out the similar 26S Proteasome Structure and Function of this human transcriptional elongation factor IIS 51 tool transcription factor.
Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in＜210〉1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has＜210〉2 protein or polypeptide, but with the differentiated nucleotide sequence of coding region sequence shown in＜210〉1.
The polynucleotide of the mature polypeptide of coding＜210〉2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.
Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.
The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.
The invention still further relates to and the polynucleotide (have at least 50% between two sequences, preferably have 70% homogeny) of sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ ID NO:2.
The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, " nucleic acid fragment " length contain 10 Nucleotide at least, better be 20-30 Nucleotide at least, be more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate the polynucleotide of coding human transcriptional elongation factor IIS 51.
Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.
The special polynucleotide sequence of coding human transcriptional elongation factor IIS 51 of the present invention can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homologous polynucleotide sequence and 2) antibody screening of expression library to be to detect the polynucleotide passage of the clone with common structure feature.
Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.
In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., MolecularCloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.
Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) appearance of marker gene function or forfeiture; (3) level of the transcript of mensuration human transcriptional elongation factor IIS 51; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.
In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.
In (4) kind method, detect the protein product of human transcriptional elongation factor IIS 51 genetic expression and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.
Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.
The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can with ordinary method such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467) measure.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.
The present invention also relates to comprise the carrier of polynucleotide of the present invention, and with carrier of the present invention or directly with the host cell of human transcriptional elongation factor IIS 51 encoding sequence through the genetically engineered generation, and the method that produces polypeptide of the present invention through recombinant technology.
Among the present invention, the polynucleotide sequence of coding human transcriptional elongation factor IIS 51 can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on the T7 promotor of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.
Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna that contains the human transcriptional elongation factor IIS 51 of encoding and the expression vector of suitable transcribing/translational control element.These methods comprise (Sambroook, et al.Molecular Cloning, aLaboratory Manual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The P of lambda particles phage
LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.
In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.
Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.
Among the present invention, the polynucleotide of coding human transcriptional elongation factor IIS 51 or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Bowes melanoma cells etc.
Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results
2Method is handled, and used step is well-known in this area.Alternative is to use MgCl
2If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.
By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce human transcriptional elongation factor IIS 51 (Science, 1984 of reorganization; 224:1431).In general following steps are arranged:
(1). with the polynucleotide (or varient) of coding of the present invention people human transcriptional elongation factor IIS 51, or with the recombinant expression vector that contains these polynucleotide proper host cell that transforms or transduce;
(2). in suitable medium, cultivate host cell;
(3). separation, protein purification from substratum or cell.
In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.
In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.
The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat malignant tumour, adrenal gland defect, tetter, all kinds of inflammation, HIV infection and immunological disease etc.
Because polypeptide of the present invention wide expression in tissue, therefore, the termination site that polypeptide people transcriptional elongation factor 51 of the present invention (HTEFIIS51) makes rna plymerase ii to cross in the transcription to be run into has guaranteed the integrity and the fidelity of transcribing.Polypeptide of the present invention in addition wide expression in tissue, therefore, polypeptide of the present invention can be used for diagnosis and treats a lot of diseases, as malignant tumour, endocrine system disease, nervous system disorders, immunological disease, people's acquired immune deficiency syndrome (AIDS) or the like.
Polypeptide of the present invention can be used for treating people's malignant tumour, includes but not limited to cancer of the stomach, liver cancer, large bowel cancer, mammary cancer, lung cancer, prostate cancer, cervical cancer, carcinoma of the pancreas, esophagus cancer.
Polypeptide of the present invention can be regulated and control micromolecular expression such as some albumen and hormone, thereby plays the therapeutic action to endocrine system disease and nervous system disorders.
Polypeptide of the present invention is a kind of immunomodulator, has immunological enhancement or immunosuppressive action.Polypeptide of the present invention can be used for the treatment of some diseases, and these diseases comprise immunoreactive anergy, or abnormal immune reaction, or the host defend invalid.Polypeptide of the present invention and its antibody also have effect to damage, defective or the imbalance class disease of immuning tissue, particularly for disease of hematopoietic system (as pernicious anemia), tetter (as psoriasis), autoimmune disease (as rheumatoid arthritis), radiation disease and immune lymphocytic generation and adjusting have extremely close relation.
The present invention also provides SCREENED COMPOUND to identify the method that improves (agonist) or check the medicament of (antagonist) human transcriptional elongation factor IIS 51.Agonist improves human transcriptional elongation factor IIS 51 biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can in the presence of medicine, the film preparation of mammalian cell or expressing human transcriptional elongation factor IIS 51 be cultivated with the human transcriptional elongation factor IIS 51 of mark.Measure the medicine raising then or check this interactional ability.
The antagonist of human transcriptional elongation factor IIS 51 comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The antagonist of human transcriptional elongation factor IIS 51 can combine and eliminate its function with human transcriptional elongation factor IIS 51, or suppresses the generation of this polypeptide, or combines with the avtive spot of this polypeptide and to make this polypeptide can not bring into play biological function.
In screening during as the compound of antagonist, human transcriptional elongation factor IIS 51 can be added during bioanalysis measures, by measuring compound interactional influence between human transcriptional elongation factor IIS 51 and its acceptor is determined whether compound is antagonist.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with human transcriptional elongation factor IIS 51 bonded peptide molecule obtains.During screening, generally tackle the human transcriptional elongation factor IIS 51 molecule and carry out mark.
The invention provides and use polypeptide, and fragment, derivative, analogue or their cell are as the method for antigen with production antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody at the human transcriptional elongation factor IIS 51 antigenic determinant.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.
The method of the available human transcriptional elongation factor IIS 51 direct injection of the production of polyclonal antibody immune animal (as rabbit, mouse, rat etc.) obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.The technology of monoclonal antibody of preparation human transcriptional elongation factor IIS 51 include but not limited to hybridoma technology (Kohler and Milstein.Nature, 1975,256:495-497), three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the single-chain antibody of anti-human transcriptional elongation factor IIS 51.
The antibody of anti-human transcriptional elongation factor IIS 51 can be used in the immunohistochemistry technology, detects the human transcriptional elongation factor IIS 51 in the biopsy specimen.
With the also available labelled with radioisotope of human transcriptional elongation factor IIS 51 bonded monoclonal antibody, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.
Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As the monoclonal antibody of human transcriptional elongation factor IIS 51 high-affinity can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing the human transcriptional elongation factor IIS 51 positive cells.
The disease that antibody among the present invention can be used for treating or prevention is relevant with human transcriptional elongation factor IIS 51.The antibody that gives suitable dosage can stimulate or block the generation or the activity of human transcriptional elongation factor IIS 51.
The invention still further relates to the diagnostic testing process of quantitative and detection and localization human transcriptional elongation factor IIS 51 level.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The human transcriptional elongation factor IIS 51 level that is detected in the test can be with laying down a definition the importance of human transcriptional elongation factor IIS 51 in various diseases and be used to the disease of diagnosing human transcriptional elongation factor IIS 51 to work.
Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.
The polynucleotide of coding human transcriptional elongation factor IIS 51 also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the nothing expression of human transcriptional elongation factor IIS 51 or the unusual/non-activity expression.The gene therapy vector (as virus vector) of reorganization can be designed for the human transcriptional elongation factor IIS 51 of expressing variation, to suppress endogenic human transcriptional elongation factor IIS 51 activity.For example, a kind of human transcriptional elongation factor IIS 51 of variation can be the human transcriptional elongation factor IIS 51 that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the disease of human transcriptional elongation factor IIS 51 expression or active caused by abnormal.Deriving from viral expression vector such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for the polynucleotide of coding human transcriptional elongation factor IIS 51 are transferred in the cell.The method of recombinant viral vector that structure carries the polynucleotide of coding human transcriptional elongation factor IIS 51 is found in existing document (Sambrook, et al.).The polynucleotide of reorganization coding human transcriptional elongation factor IIS 51 can be packaged in the liposome and be transferred in the cell in addition.
Polynucleotide import tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.
Suppress the oligonucleotide (comprising sense-rna and DNA) of human transcriptional elongation factor IIS 51 mRNA and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.
The polynucleotide of coding human transcriptional elongation factor IIS 51 can be used for the diagnosis with the relative disease of human transcriptional elongation factor IIS 51.The unconventionality expression of the expression that the polynucleotide of coding human transcriptional elongation factor IIS 51 can be used for detecting human transcriptional elongation factor IIS 51 human transcriptional elongation factor IIS 51 whether or under morbid state.As the dna sequence dna of the human transcriptional elongation factor IIS 51 of encoding can be used for biopsy specimen is hybridized to judge the expression situation of human transcriptional elongation factor IIS 51.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect human transcriptional elongation factor IIS 51 with the special primer of human transcriptional elongation factor IIS 51.
The sudden change that detects the human transcriptional elongation factor IIS 51 gene also can be used for the disease of diagnosing human transcriptional elongation factor IIS 51 relevant.The form of human transcriptional elongation factor IIS 51 sudden change comprises that the point mutation compared with normal wild type human transcriptional elongation factor IIS 51 dna sequence dna, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.
Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.
In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.
The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).
The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manualof Basic Techniques, Pergamon Press, New York (1988).
In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, Mendelian Inheritancein Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.
Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.
Polypeptide of the present invention, polynucleotide and stand-in thereof, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back can be used.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.
The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.
Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.Human transcriptional elongation factor IIS 51 comes administration with the amount that treats and/or prevents concrete indication effectively.The amount and the dosage range that are applied to patient's human transcriptional elongation factor IIS 51 will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.
Description of drawings
Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.
Fig. 1 is the amino acid sequence homology comparison diagram of inventor's transcriptional elongation factor IIS 51 and human transcription factor TFIIS.The top sequence is a human transcriptional elongation factor IIS 51, and the below sequence is human transcription factor TFIIS.Same amino acid represents with monocase amino acid that between two sequences similar amino acid is represented with "+".
Fig. 2 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of isolating human transcriptional elongation factor IIS 51.51kDa is proteinic molecular weight.The arrow indication is isolated protein band.
Embodiment
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold SpringHarbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
Embodiment 1: the clone of human transcriptional elongation factor IIS 51
Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure all clones' 5 ' and 3 ' terminal sequence with Dyeterminate cycle reaction sequencing kit (Perkin-Elmer company product) and ABI 377 automatic sequencers (Perkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, found that the cDNA sequence of one of them clone 0794c11 is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 0794c11 clone is 2861bp (as＜210〉1 shown in), from 32bp to 592bp the open reading frame (ORF) of a 561bp arranged, the new protein of encoding (as＜210〉2 shown in).We are with this clone's called after pBS-0794c11, encoded protein matter called after human transcriptional elongation factor IIS 51.Embodiment 2:cDNA clone's homology retrieval
With the sequence and the encoded protein sequence thereof of human transcriptional elongation factor IIS 51 of the present invention, with Blast program (Basiclocal Alignment search tool) [Altschul, SF et al.J.Mol.Biol.1990; 215:403-10], carry out the homology retrieval at databases such as Genbank, Swissport.The gene the highest with human transcriptional elongation factor IIS 51 homology of the present invention is a kind of known human transcription factor TFIIS, and its encoded protein number is D87685 in the access of Genbank.Protein homology the results are shown in Fig. 1, both height homologies, and its homogeny is 99%.Embodiment 3: with the gene of RT-PCR method clones coding human transcriptional elongation factor IIS 51
Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:
Primer1：5′-GGATTAGATTCTAAGCATAAGTG-3′ (<210>3)
Primer2：5′-TTATGACCTTCATACTTTATTAC-3′ (<210>4)
Primer1 for to be positioned at＜the forward sequence that begins of 1bp of 210〉15 ' end;
Primer2 be＜210〉1 in 3 ' end reverse sequence.
The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/LTris-Cl, (pH8.5), 1.5mmol/L MgCl
2, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows the dna sequence dna and＜210 of PCR product〉1-1900bp shown in 1 is identical.Embodiment 4:Northern blotting analyst transcriptional elongation factor IIS 51 expression of gene:
Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) carries out homogenate to tissue, adds the phenol of 1 times of volume and the chloroform-primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (0.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ g RNA, on 1.2% sepharose that contains 20mM 3-(N-morpholino) propanesulfonic acid (pH7.0)-5mM sodium acetate-1mM EDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α-
32P dATP prepares by random priming
32The dna probe of P-mark.Used dna probe is the human transcriptional elongation factor IIS 51 coding region sequence (124bp to 1515bp) of pcr amplification shown in Figure 1.Probe (about 2 * 10 with the 32P-mark
6Cpm/ml) spend the night in 42 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mM KH
2PO
4(pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with Phosphor Imager.Embodiment 5: the vivoexpression of recombinant human transcriptional elongation factor IIS 51, separation and purifying
According to＜210〉1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:
Primer3：5′-CCCCATATGATGGAATGTAAAGCCAAGCCTG-3′(<210>5)
Primer4：5′-CCCGGATCCTCATACACACATACACACACACC-3′(<210>6)
5 ' end of these two sections primers contains NcoI and BamHI restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, NcoI and BamHI restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-0794c11 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-0794c11 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with NcoI and BamHI, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-0794c11) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) plySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-0794c11) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant with carrying out chromatography with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product), has obtained the target protein human transcriptional elongation factor IIS 51 of purifying.Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 2) at the 51kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end are identical with 15 amino-acid residues of N-end shown in＜210〉2 as a result.Embodiment 6 anti-human transcriptional elongation factor IIS 51 production of antibodies
Synthesize the specific polypeptide of following human transcriptional elongation factor IIS 51 with Peptide synthesizer (PE company product):
NH2-Met-Glu-Cys-Lys-Ala-Lys-Pro-Val-Gly-Ser-Pro-Leu-Phe-Lys-Phe-COOH。Form compoundly with hemocyanin and bovine serum albumin coupling this polypeptide respectively, method is referring to Avrameas, et al.Immunochemistry, 1969; 6:43.Add the complete Freund's adjuvant immunizing rabbit with the above-mentioned hemocyanin polypeptide complex of 4mg, add the incomplete Freund's adjuvant booster immunization once with the hemocyanin polypeptide complex again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml bovine serum albumin polypeptide complex bag quilts.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with human transcriptional elongation factor IIS 51 specifically.
Sequence table＜110〉Bode Gene Development Co., Ltd., Shanghai＜120 a kind of polypeptide-human transcriptional elongation factor IIS 51 and the coding this peptide species polynucleotide＜130 0794c11＜160 14＜170〉Patent In version 3.1＜210 1＜211〉1900＜212〉DNA＜213〉Homo sapiens＜220＜221〉CDS＜222, (32) .., (592)＜223〉＜400〉1ggattagatt ctaagcataa gtgtaataat c cgg gag aaa tag atg tgc cat 52
Arg?Glu?Lys Met?Cys?His
1 5ctc?atg?aat?taa?att?gtt?cac?ttc?ttt?cag?aga?ctt?gtg?tta?cta?ttg 100Leu?Met?Asn Ile?Val?His?Phe?Phe?Gln?Arg?Leu?Val?Leu?Leu?Leu
10 15 20gag?aaa?aga?aaa?atg?aag?ctt?tga?tgg?aat?gta?aag?cca?agc?ctg?ttg 148Glu?Lys?Arg?Lys?Met?Lys?Leu Trp?Asn?Val?Lys?Pro?Ser?Leu?Leu
25 30 35gta?gtc?cat?tgt?tta?agt?ttt?cag?ata?aag?aag?aac?atg?aac?aaa?atg 196Val?Val?His?Cys?Leu?Ser?Phe?Gln?Ile?Lys?Lys?Asn?Met?Asn?Lys?Met
40 45 50att?cca?ttt?cag?gta?aaa?cgg?gtg?aga?ctg?ttg?ttg?aag?aaa?tga?tag 244Ile?Pro?Phe?Gln?Val?Lys?Arg?Val?Arg?Leu?Leu?Leu?Lys?Lys
55 60 65caa?caa?gaa?aag?ttg?aac?aag?att?caa?agg?aga?cag?taa?aat?tat?ccc 292Gln?Gln?Glu?Lys?Leu?Asn?Lys?Ile?Gln?Arg?Arg?Gln Asn?Tyr?Pro
70 75 80atg?aag?atg?acc?ata?ttc?ttg?agg?acg?ctg?gat?ctt?ctg?ata?ttt?cta 340Met?Lys?Met?Thr?Ile?Phe?Leu?Arg?Thr?Leu?Asp?Leu?Leu?Ile?Phe?Leu
85 90 95gtg?atg?ctg?ctt?gta?caa?atc?caa?ata?aga?cag?aaa?aca?gcc?ttg?tag 388Val?Met?Leu?Leu?Val?Gln?Ile?Gln?Ile?Arg?Gln?Lys?Thr?Ala?Leu
100 105 110gtt?tgc?cta?gtt?gtg?tag?atg?aag?tga?ctg?aat?gta?att?tgg?aat?tga 436Val?Cys?Leu?Val?Val Met?Lys Leu?Asn?Val?Ile?Trp?Asn
115 120 125agg?ata?cca?tgg?gta?ttg?ctg?ata?aaa?ctg?aga?aca?ccc?ttg?aaa?gaa 484Arg?Ile?Pro?Trp?Val?Leu?Leu?Ile?Lys?Leu?Arg?Thr?Pro?Leu?Lys?Glu
130 135 140ata?aaa?ttg?aac?cgt?tgg?gtt?att?gtg?aag?atg?cgg?agt?cta?ata?ggc 532Ile?Lys?Leu?Asn?Arg?Trp?Val?Ile?Val?Lys?Met?Arg?Ser?Leu?Ile?Gly
145 150 155agt?tgg?aga?gca?ctg?agt?tta?ata?aat?caa?act?tag?agg?tgg?ttg?ata 580Ser?Trp?Arg?Ala?Leu?Ser?Leu?Ile?Asn?Gln?Thr Arg?Trp?Leu?Ile
160 165 170cta?gta?ctt?ttg?gaccggaaag?taatatcttg?gaaaatgcta?tttgtgatgt 632Leu?Val?Leu?Leu
175gcctgaccaa?aattcaaaac?agttgaatgc?tatagaaagt?actaaaatag?agtcccatga 692aacagcaaac?cttcaggatg?acagaaacag?ccagtcaagt?agcgtttctt?acttagagtc 752aaaaagtgta?aaatccaaac?atacaaaacc?tgtaattcat?tctaagcaaa?acatgaccac 812agatgctccg?aagaaaattg?ttgcagcaaa?gtatgaagta?atacatagca?aaactaaagt 872taatgtcaaa?agtgtgaaac?gaaatactga?tgtaccagaa?tctcagcaaa?attttcatag 932gccagtcaaa?gtcagaaaaa?aacaaattga?taaggagcca?aagattcaga?gttgcaattc 992tggggttaaa?tctgtgaaaa?accaagctca?ttctgtactg?aaaaaaacat?tacaggatca 1052aactttagta?caaattttca?agcccttaac?tcattctttg?agtgataagt?cacacgctca 1112tcctggttgc?ttgaaagaac?ctcatcatcc?tgcacaaact?ggacatgtat?cacattctag 1172ccagaaacag?tgtcataagc?ctcagcaaca?ggccccagca?atgaaaacca?atagtcacgt 1232gaaggaagag?cttgaacacc?caggcgttga?gcattttaag?gaagaggata?aactgaaact 1292gaaaaaacct?gagaagaacc?tacaaccccg?ccaaagaaga?agcagcaaaa?gtttttcttt 1352agatgagcca?ccattgttca?ttccagataa?catagctacc?ataagaagag?aaggctctga 1412tcatagctcc?tcatttgaaa?gcaaatatat?gtggactccc?agcaagcagt?gtgggttttg 1472caaaaaacca?catggcaaca?ggtgtgtgtg?tatgtgtgta?tgagtgatgt?gtacattgaa 1532aataaattgc?ttttttgggg?gtgggattaa?tgtgagaatt?gttttaaaga?cattatttga 1592tacacagaga?cctgtgcaaa?aacaaaaagc?ttcatcagtc?ttggataaat?gatagaaaga 1652tggatctact?gaatttacaa?atatatcatc?ctagaacatt?taaaaaagca?tagtctggcc 1712aacagctgac?atacatggaa?atattttgtc?attgtcacag?gttagacagt?gtaatttagc 1772cactgcatct?gcaaaaaagc?caaacacttc?ctggtaattg?gaaaattgtt?atactgcttt 1832gggtctgtaa?gttatatatt?aattcatttg?gtgtgagaag?aactagtaat?aaagtatgaa 1892ggtcataa1900<210> 2<211> 6<212> PRT<213> Homo?sapiens<400> 2Met?Cys?His?Leu?Met?Asn1 5<210> 3<211> 19<212> PRT<213> Homo?sapiens<400> 3Ile?Val?His?Phe?Phe?Gln?Arg?Leu?Val?Leu?Leu?Leu?Glu?Lys?Arg?Lys1 5 10 15Met?Lys?Leu<210> 4<211> 38<212> PRT<213> Homo?sapiens<400> 4Trp?Asn?Val?Lys?Pro?Ser?Leu?Leu?Val?Val?His?Cys?Leu?Ser?Phe?Gln1 5 10 15Ile?Lys?Lys?Asn?Met?Asn?Lys?Met?Ile?Pro?Phe?Gln?Val?Lys?Arg?Val
20 25 30Arg?Leu?Leu?Leu?Lys Lys
35<210> 5<211> 12<212> PRT<213> Homo?sapien?s<400> 5Gln?Gln?Glu?Lys?Leu?Asn?Lys?Ile?Gln?Arg?Arg?Gln1 5 10<210> 6<211> 34<212> PRT<213> Homo?sapiens<400> 6Asn?Tyr?Pro?Met?Lys?Met?Thr?Ile?Phe?Leu?Arg?Thr?Leu?Asp?Leu?Leu1 5 10 15Ile?Phe?Leu?Val?Met?Leu?Leu?Val?Gln?Ile?Gln?Ile?Arg?Gln?Lys?Thr
20 25 30Ala?Leu<210> 7<211> 5<212> PRT<213> Homo?sapiens<400> 7Val?Cys?Leu?Val?Val1 5<210> 8<211> 6<212> PRT<213> Homo?sapiens<400> 8Leu?Asn?Val?Ile?Trp?Asn1 5<210> 9<211> 43<212> PRT<213> Homo?sapiens<400> 9Arg?Ile?Pro?Trp?Val?Leu?Leu?Ile?Lys?Leu?Arg?Thr?Pro?Leu?Lys?Glu1 5 10 15Ile?Lys?Leu?Asn?Arg?Trp?Val?Ile?Val?Lys?Met?Arg?Ser?Leu?Ile?Gly
20 25 30Ser?Trp?Arg?Ala?Leu?Ser?Leu?Ile?Asn?Gln?Thr
35 40<210> 10<211> 8<212> PRT<213> Homo?sapiens<400> 10Arg?Trp?Leu?Ile?Leu?Val?Leu?Leu1 5<210> 11<211> 23<212> DNA<213> Homo?sapiens<400> 11ggattagatt?ctaagcataa?gtg23<210> 12<211> 23<212> DNA<213> Homo?sapiens<400> 12ttatgacctt?catactttat?tac23<210> 13<211> 31<212> DNA<213> Homo?sapiens<400> 13ccccatatga tggaatgtaa agccaagcct g31<210> 14<211> 32<212> DNA<213> Homo?sapiens<400> 14cccggatcct?catacacaca?tacacacaca?cc32
Claims (18)
1, a kind of isolated polypeptide-human transcriptional elongation factor IIS 51 is characterized in that it includes: the polypeptide of the aminoacid sequence shown in＜210〉2 or the active fragments of its polypeptide, analogue or derivative.
2, polypeptide as claimed in claim 1, the aminoacid sequence that it is characterized in that described polypeptide, analogue or derivative has the homogeny with the aminoacid sequence at least 95% shown in＜210〉2.
3, polypeptide as claimed in claim 2 is characterized in that it comprises and has＜polypeptide of the aminoacid sequence shown in 210〉2.
4, a kind of isolating polynucleotide, it is characterized in that described polynucleotide comprise be selected from down the group in a kind of:
(a) coding have＜210〉2 shown in the polynucleotide of the polypeptide of aminoacid sequence or its fragment, analogue, derivative;
(b) with polynucleotide (a) complementary polynucleotide; Or
(c) with (a) or the polynucleotide of at least 99% homogeny (b) are arranged.
5, polynucleotide as claimed in claim 4, it is characterized in that described polynucleotide comprise coding and have＜210〉2 shown in the polynucleotide of aminoacid sequence.
6, polynucleotide as claimed in claim 4, it is characterized in that the sequence of described polynucleotide includes＜210〉1 in the 124-1515 position sequence or＜210〉1 in the sequence of 1-1900 position.
7, a kind of recombinant vectors that contains exogenous polynucleotide is characterized in that it is the recombinant vectors that is formed by the described polynucleotide of arbitrary claim among the claim 4-6 and plasmid, virus or vehicle expression vector establishment.
8, a kind of genetically engineered host cell that contains exogenous polynucleotide is characterized in that it is to be selected from following a kind of host cell:
(a) host cell that transforms or transduce with the described recombinant vectors of claim 7; Or
(b) host cell that transforms or transduce with the described polynucleotide of the arbitrary claim among the claim 4-6.
9, a kind of preparation method with the active polypeptide of human transcriptional elongation factor IIS 51 is characterized in that described method comprises:
(a) under expressing human transcriptional elongation factor IIS 51 condition, cultivate the described through engineering approaches host cell of claim 8;
(b) from culture, isolate and have the active polypeptide of human transcriptional elongation factor IIS 51.
10, a kind of can with polypeptide bonded antibody, it is characterized in that described antibody be can with human transcriptional elongation factor IIS 51 specificity bonded antibody.
11, the compound of an analoglike or adjusting polypeptide active or expression is characterized in that they are simulation, promotion, antagonism or the active compound that suppresses human transcriptional elongation factor IIS 51.
12, compound as claimed in claim 11 is characterized in that it is＜polynucleotide sequence or its segmental antisense sequences shown in 210〉1.
13, the described application of compound of a kind of claim 11, it is characterized in that described compound be used for mediator's transcriptional elongation factor IIS 51 in vivo, the method for external activity.
14, a kind of disease relevant or method of disease susceptibility of detecting with the described polypeptide of arbitrary claim among the claim 1-3, it is characterized in that it comprises the described polypeptide expression amount that detects, perhaps detect the activity of described polypeptide, perhaps detect and cause described expression of polypeptides amount or active unusual nucleotide diversity in the polynucleotide.
15, as the application of polypeptide as described in the arbitrary claim among the claim 1-3, it is characterized in that it is applied to screen the stand-in of human transcriptional elongation factor IIS 51, agonist, antagonist or inhibitor; Perhaps be used for the peptide finger print identification.
16, as the application of the described nucleic acid molecule of arbitrary claim among the claim 4-6, it is characterized in that it is used for nucleic acid amplification reaction as primer, perhaps be used for hybridization, perhaps be used to make gene chip or microarray as probe.
17,, it is characterized in that forming pharmaceutical composition with safe and effective dosage and pharmaceutically acceptable carrier as diagnosis or the treatment disease relevant unusually with human transcriptional elongation factor IIS 51 with described polypeptide, polynucleotide or its stand-in, agonist, antagonist or inhibitor as the described polypeptide of arbitrary claim, polynucleotide or application of compound in claim 1-6 and 11.
18, the described polypeptide of arbitrary claim, polynucleotide or the application of compound among the claim 1-6 and 11, it is characterized in that being used for the treatment of malignant tumour with described polypeptide, polynucleotide or compound, hemopathy, the medicine of HIV infection and immunological disease and all kinds of inflammation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021362335A CN1470524A (en) | 2002-07-26 | 2002-07-26 | Polypeptide-human transcriptional elongation factor IIS51 and polynucleotide encoding this polypeptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021362335A CN1470524A (en) | 2002-07-26 | 2002-07-26 | Polypeptide-human transcriptional elongation factor IIS51 and polynucleotide encoding this polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1470524A true CN1470524A (en) | 2004-01-28 |
Family
ID=34146361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021362335A Pending CN1470524A (en) | 2002-07-26 | 2002-07-26 | Polypeptide-human transcriptional elongation factor IIS51 and polynucleotide encoding this polypeptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1470524A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107266540A (en) * | 2017-07-19 | 2017-10-20 | 福州大学 | A kind of preparation method of mycobacterium tuberculosis elongation factors EF Tu albumen |
-
2002
- 2002-07-26 CN CNA021362335A patent/CN1470524A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107266540A (en) * | 2017-07-19 | 2017-10-20 | 福州大学 | A kind of preparation method of mycobacterium tuberculosis elongation factors EF Tu albumen |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1302897A (en) | Polypeptide-human phosphodiesterase 21 similar to acidic sphingomyelinase and polynucleotide for coding it | |
| CN1470524A (en) | Polypeptide-human transcriptional elongation factor IIS51 and polynucleotide encoding this polypeptide | |
| CN1303931A (en) | Novel polypeptide-XRN-100 and polynucleotide coding said polypeptide | |
| CN1477123A (en) | A polypeptide-transcription factor 43 and polynucleotide coding said polypeptide | |
| CN1303939A (en) | Novel polypeptide-transcription factor 43 and polynucleotide coding said polypeptide | |
| CN1303930A (en) | Novel polypeptide-zinc finger protein 57 and polynucleotide coding said polypeptide | |
| CN1302881A (en) | Polypeptide-human beta-galactoside binding protein and polynucleotide for coding it | |
| CN1303944A (en) | Novel polypeptide-threonine synthetase 71 and polynucleotide coding said polypeptide | |
| CN1292385A (en) | New polypeptide-human DNA-PK interaction protein 75 and polynucleotide coding this polypeptide | |
| CN1302886A (en) | Polypeptide-human cell wither correlated protein 12 and polynucleotide for coding it | |
| CN1303937A (en) | Novel polypeptide-human tissue anion transport polypeptide 41 and polynucleotide coding said polypeptide | |
| CN1302874A (en) | Polypeptide-translation initiation factor helper factor 28 and polynucleotide for coding it | |
| CN1302871A (en) | Polypeptide-human vacuolus proton-adenosine triphosphatase C subunit 42 and polynucleotide for coding it | |
| CN1303866A (en) | Novel polypeptide-zinc finger protein 36 and polynucleotide for coding this polypeptide | |
| CN1302888A (en) | Polypeptide-human rigor factor 23 and polynucleotide for coding it | |
| CN1302887A (en) | Polypeptide-dyein light-medium chain 58 and polynucleotide for coding it | |
| CN1464049A (en) | New polypeptide-human sailer transposase 11 and polynucleotides for coding same | |
| CN1302880A (en) | Polypeptide-human shearing factor 25 and polynucleotide for coding it | |
| CN1303938A (en) | Novel polypeptide-human MATH37 and polynucleotide coding said polypeptide | |
| CN1470527A (en) | Polypeptide-human calcium ion regulatory secretory action protein 48 and polynucleotide encoding this polypeptide | |
| CN1303863A (en) | Novel polypeptide-human transcriptional elongation factor IIS51 and polynucleotide for coding this polypeptide | |
| CN1302889A (en) | Polypeptide-human protein 70 containing plasmolemma regulation function and polynucleotide for coding it | |
| CN1303862A (en) | Novel polypeptide-human shearing and polyadenylation specific factor subunit 66 and polynucleotide for coding said polypeptide | |
| CN1296968A (en) | Polypeptide-human karyon regulatory protein 56 and polynucleotide for coding said polypeptide | |
| CN1477120A (en) | A polypeptide-human tissue anion transport polypeptide 41 and polynucleotide coding said polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |